Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 2.21e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 1.00e-3 | 2.57e-2 |
CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-2 | 1.05e-2 |
Internalizing Problems | Internalizing Problems | ETC | Benke | 2014 | NA | 4596 | 1.00e-2 | 8.16e-3 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-2 | 1.04e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 5.00e-2 | 3.22e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 6.82e-3 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-3 | 2.69e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 5.00e-2 | 4.46e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-2 | 2.27e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-3 | 1.58e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-3 | 3.21e-2 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-2 | 3.07e-2 |
Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 5.00e-2 | 1.63e-2 |
Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 1.00e-2 | 2.67e-3 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 5.00e-2 | 7.22e-3 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 5.00e-2 | 5.27e-4 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-2 | 2.05e-5 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-3 | 1.62e-4 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-4 | 2.36e-3 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-5 | 1.02e-2 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 5.84e-4 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.55e-5 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 3.74e-4 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.22e-6 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 1.48e-4 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 8.92e-3 |
Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 4.33e-2 |
Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 3.92e-2 |
BMI Physical Activity Interaction | BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.90e-2 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.41e-2 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.20e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.48e-2 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 5.00e-2 | 4.38e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 2.85e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-2 | 1.76e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 3.55e-5 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 3.38e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7432 | 5.00e-2 | 1.94e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 1.00e-3 | 2.24e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-3 | 2.33e-2 |
Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.25e-2 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.21e-2 |
Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.10e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 7.20e-3 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.71e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.42e-2 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.32e-2 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.74e-2 |
Facial Shape | Mod53 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.39e-2 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 1.65e-3 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.26e-2 |
Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 2.09e-2 |
Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-3 | 2.96e-3 |
Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-4 | 4.62e-3 |
Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 5.00e-2 | 2.78e-3 |
Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 1.00e-2 | 2.52e-4 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 1.04e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 2.94e-3 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 3.52e-2 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-3 | 4.35e-2 |
Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 2.86e-2 |
Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 3.67e-2 |
Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-4 | 1.90e-2 |
Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-5 | 1.37e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-2 | 1.55e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 1.73e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 1.18e-3 |
Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 3.41e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.82e-3 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.78e-5 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.50e-6 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 2.82e-2 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.88e-5 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 5.72e-3 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 5.00e-2 | 2.48e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 4.77e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 9.26e-3 |
PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 3.69e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 1.68e-2 |
EOC | Epithelial Ovarian Cancer | ETC | Phelan | 2017 | 25509 | 40941 | 5.00e-2 | 8.31e-4 |
EOC | Epithelial Ovarian Cancer | ETC | Phelan | 2017 | 25509 | 40941 | 1.00e-2 | 1.04e-2 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 4.31e-2 |
K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 3.36e-2 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-5 | 4.90e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-5 | 4.77e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 7.00e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-4 | 1.88e-2 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 1.00e-4 | 4.56e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 3.09e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-5 | 3.39e-2 |
Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-2 | 4.37e-2 |
Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-5 | 4.24e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 4.84e-2 |
Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 2.47e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 2.44e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 1.00e-2 | 4.74e-2 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 7.77e-3 |
Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-2 | 2.09e-2 |
BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 1.83e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 1.10e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-4 | 3.50e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 6.96e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 5.41e-4 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 2.31e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 1.15e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-5 | 4.34e-2 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-2 | 3.36e-2 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-3 | 6.01e-3 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-4 | 2.87e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-2 | 1.76e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 1.00e-2 | 2.13e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 1.54e-2 |
COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 5.00e-2 | 3.05e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.